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Abstract
Multidrug-resistant clinical isolates are common in certain pathogens, but rare in others. This pattern may be due to the
fact that mutations shaping resistance have species-specific effects. To investigate this issue, we transferred a range of
resistance-conferring mutations and a full resistance gene into Escherichia coli and closely related bacteria. We found that
resistance mutations in one bacterial species frequently provide no resistance, in fact even yielding drug hypersensitivity
in close relatives. In depth analysis of a key gene involved in aminoglycoside resistance (trkH) indicated that preexisting
mutations in other genes—intergenic epistasis—underlie such extreme differences in mutational effects between species.
Finally, reconstruction of adaptive landscapes under multiple antibiotic stresses revealed that mutations frequently
provide multidrug resistance or elevated drug susceptibility (i.e., collateral sensitivity) only with certain combinations of
other resistance mutations. We conclude that resistance and collateral sensitivity are contingent upon the genetic
makeup of the bacterial population, and such contingency could shape the long-term fate of resistant bacteria. These
results underlie the importance of species-specific treatment strategies.
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Introduction
The rapid emergence and spread of antibiotic resistance
mechanisms in bacteria may soon lead to a world-wide health
crisis of grave proportions (Bush et al. 2011). As the develop-
ment and discovery of novel drugs has slowed significantly
over recent decades, alternative avenues to combat resistant
microbes are required (Laxminarayan 2014). Multidrug strat-
egies aim to exploit the evolutionary trade-offs that resistance
mutations present by identifying pairs of drugs where adap-
tation to one antibiotic simultaneously induces susceptibility
to another (Baym et al. 2016). This phenomenon, known as
collateral sensitivity (Pal et al. 2015), was first observed in a
pioneering study 65 years ago (Szybalski and Bryson 1952).
Recent years have seen a renewed focus on the characteriza-
tion and potential exploitation of collateral sensitivity phe-
nomena (Pal et al. 2015; Baym et al. 2016) with several in vitro,
system-wide studies revealing general patterns (Imamovic
and Sommer 2013; Lazar et al. 2013, 2014; Munck et al.
2014; Oz et al. 2014; Rodriguez de Evgrafov et al. 2015;
Imamovic et al. 2018) and specific molecular mechanisms
(Lazar et al. 2013; Imamovic et al. 2018) underlying these
interactions. Rational treatment approaches such as alternat-
ing collaterally sensitive drug pairs (Imamovic and Sommer
2013; Imamovic et al. 2018; Kim et al. 2014), or the
simultaneous utilization of multiple collaterally sensitive anti-
biotics (Gonzales et al. 2015) may be viable clinical strategies
against multidrug-resistant pathogens. Additionally, the clin-
ical implications of collateral sensitivity are not limited to the
antimicrobial treatment of pathogenic bacteria but include
therapeutic approaches against cancer as well (Pluchino et al.
2012). In fact, several studies have revealed vulnerabilities of
resistant tumor cell lines against other anticancer drugs
(Jensen et al. 1997; Zhao et al. 2016; Dhawan et al. 2017;
Wang et al. 2018), indicating the therapeutic potential of
collaterally sensitive drug pairs.
Despite this significant progress in the study of collateral
sensitivity over the recent years, there are several key ques-
tions that have remained unanswered (Pal et al. 2015). Most
importantly, little is known regarding the extent of evolution-
ary conservation of multidrug resistance and collateral sensi-
tivity (fig. 1). The limited number of studies aiming to map
the networks of cross-resistance and collateral sensitivity
interactions has mostly focused on single model organisms
(Pal et al. 2015; Barbosa et al. 2017) or different strains of the
same species (Podnecky et al. 2018), leaving the question of
the universality of these findings unexplored. Recent work has
shown selected instances of conserved collateral responses of
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regardless of the strain (Podnecky et al. 2018). In another
recent study, in addition to conserved instances of collateral
responses, major differences were also observed between par-
allel samples of the same strain of Pseudomonas aeruginosa
adapted to the same antibiotic (Barbosa et al. 2017). Overall,
the impact of genetic background on such interactions
remains mostly unknown. More specifically, to what extent
does genetic epistasis influence the collateral response net-
works of antibiotic-resistant bacteria? It is well known that
the phenotypic effects of a mutation frequently depend on its
interactions with the specific genetic background; mutations
beneficial in one genetic context are often neutral or even
detrimental in another (Lehner 2011; de Visser et al. 2011).
This could be true for antimicrobial resistance mechanisms, as
mutations can have substantially different fitness effects
across species (Wong 2017).
In this work, we elucidate the evolutionary conservation of
resistance and collateral sensitivity (see fig. 1 for a conceptual
overview). By constructing a set of previously identified resis-
tance mutations in two related bacteria, E. coli and Salmonella
enterica, we directly compared the impact of resistance muta-
tions in two species. By transplanting an entire resistance-
conferring mutated gene and its wild-type counterpart
from one species to the other, we elucidated the relative roles
of intragenic epistasis (epistatic effects owing to mutational
differences within the resistance gene) and intergenic epistasis
(epistatic effects derived from mutations elsewhere in the
genome). Finally, by constructing isogenic strains carrying dif-
ferent combinations of known resistance mutations affecting
multiple genes, we observed that mutations that provide
cross-resistance in one genetic background frequently yield
collateral sensitivity in another. These results point to the
variable nature of multidrug resistance and collateral sensitiv-
ity and highlight the importance of genetic epistasis as an
underlying driving force.
Results
Mutations Can Have Opposite Effects on
Susceptibility in Different Species
Our first aim was to investigate the level of conservation of
mutational effects in two related bacterial species. Based on
results of a prior study (Lazar et al. 2014), we selected ten
point mutations that influence susceptibility to multiple anti-
biotics in E. coli strain BW25113. The corresponding genes
encode proteins involved in various cellular processes includ-
ing regulation of efflux pumps, maintenance of membrane
permeability, or transcriptional control of general stress-
defense mechanisms (supplementary table 1,
Supplementary Material online). Importantly, many of these
genes have been implicated in cases of clinical resistance
(Okusu et al. 1996; Piddock 2006; Alekshun and Levy 2007).
Using the pORTMAGE recombineering method, applica-
ble to a range of bacterial species (Nyerges et al. 2016), we
constructed these ten mutations individually in both E. coli
BW25113 (Grenier et al. 2014) and S. enterica subsp. serovar
Typhimurium strain LT2 (McClelland et al. 2001). This tech-
nique is especially suitable for such purposes, as it allows the
genomic incorporation of specific point mutations without
detectable off-target mutations (Nyerges et al. 2016). The
selected genes are generally highly conserved between the
two species with amino acid sequence similarities ranging
FIG. 1. Evolutionary conservation of cross-resistance and collateral sensitivity. The conceptual figure displays the impact of a hypothetical
mutation on antibiotic 1 and antibiotic 2 susceptibilities. Resistance changes in the two hypothetical bacterial genetic backgrounds are indicated
by blue solid and red dashed arrows. The mutation increases resistance level to antibiotic 1 in both genetic backgrounds. It may increase resistance
to antibiotic 2 in both genetic backgrounds (conserved cross-resistance), increase susceptibility to antibiotic 2 in both genetic backgrounds
(conserved collateral sensitivity), or change susceptibility to antibiotic 2 in a different manner in the two genetic backgrounds (intergenic epistasis
dependent effect).








be/article-abstract/36/8/1601/5486065 by guest on 21 N
ovem
ber 2019
from 79% to 100%, with an average of 91.2%. Importantly, the
specific mutated amino acid residues are also conserved in all
ten cases. Next, we compared the impact of these mutations
on resistance against a panel of 12 antibiotics with different
modes of action (table 1). Using an established liquid culture-
based standard broth dilution technique (Lazar et al. 2013),
the minimum inhibitory concentration (MIC) values of each
mutant strain against a panel of clinically relevant antibiotics
were determined in E. coli BW25113 and S. enterica LT2 (table 2
and supplementary File 1, Supplementary Material online, for
raw data). Previously, we have demonstrated that the protocol
can reliably detect as small as 10% differences in MICs across
mutant strains (Lazar et al. 2014). The relative difference in MIC
values between the wild-type and the specific mutant gives an
estimate on the effect of a particular mutation on antibiotic
susceptibility in a given species. Finally, these relative MIC val-
ues were compared in the two species (table 2).
Analysis of all possible 120 combinations of antibiotic–
mutation pairs revealed major differences in mutational
effects between the two species. Overall, in 33% of these
120 cases, a mutation that either increased or lowered the
MIC in one species had no effect in the other. Moreover, over
13% of the total mutation–antibiotic combinations displayed
antagonistic mutational effects, that is, introduction of the
mutation increased susceptibility in one species but elevated
resistance in the other. For example, a mutation in ycbZ, a
putative protease, elevated sensitivity in E. coli to the studied
aminoglycosides but had an antagonistic effect when present
in S. enterica, resulting in increased levels of resistance against
these antibiotics (fig. 2). Similarly, a mutation in acrR, a multi-
drug efflux pump regulator, caused increased sensitivity to
nalidixic acid when present in E. coli but led to increased
resistance to the same drug when present in S. enterica
(fig. 2). Even in cases where a mutation had the same phe-
notypic effect in both organisms (leading either to increased
resistance or sensitivity), the extent of the effect often varied
Table 1. List of Employed Antibiotics.




Ampicillin AMP Cell wall Bactericidal
Cefoxitin FOX Cell wall Bactericidal
Doxycycline DOX Protein synthesis,
30S
Bacteriostatic
Tertracycline TET Protein synthesis,
30S
Bacteriostatic
Chloramphenicol CHL Protein synthesis,
50S
Bacteriostatic
Erythromycin ERY Protein synthesis,
50S
Bacteriostatic
Nalidxic acid NAL Gyrase Bactericidal













NOTE.—Functional classification is based on previous studies (Yeh et al. 2006; Girgis
et al. 2009). These antibiotics are well characterized, cover a wide variety in modes of
action, and are frequently deployed in the clinic.
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NOTE.—The effect of these mutations on the susceptibility to 12 antibiotics was measured in both organisms. Blue, orange, and white colors indicate an increase, decrease, and
no change in resistance, respectively. Numbers indicate relative resistance level of the mutant compared with the corresponding wild-type, estimated by changes in MICs. For
antibiotic abbreviations, see table 1.
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greatly. For instance, the common S83L mutation of the
GyrA protein target identified in clinical E. coli isolates in
response to nalidixic acid or ciprofloxacin stress (Bagel
et al. 1999) conferred a>600-fold increment in resistance
level against nalidixic acid in S. enterica, whereas the same
figure was approximately 100-fold in E. coli BW25113
(Nyerges et al. 2016). Conversely, a mutation affecting
the outer membrane porin-encoding ompC resulted in
increased susceptibility to kanamycin in both species,
however, the effect was over four times greater when
present in E. coli compared with S. enterica.
Limited Evolutionary Conservation of Collateral
Sensitivity across Species
Evolution of resistance toward a given antibiotic can simul-
taneously decrease resistance against multiple other drugs, a
phenomenon termed collateral sensitivity (Pal et al. 2015). By
focusing on single bacterial species, prior studies have
revealed that this phenomenon is wide spread and may be
clinically relevant (Imamovic and Sommer 2013; Lazar et al.
2013, 2014; Rodriguez de Evgrafov et al. 2015; Imamovic et al.
2018). However, the evolutionary conservation of collateral
sensitivity remains largely unknown. This issue depends on
the extent of overlap in the mechanisms underlying resis-
tance and physiological trade-offs across related species. To
investigate this issue, we first focused on trkH, which encodes
a potassium ion transporter (Schlo¨sser et al. 1995). By reduc-
ing the proton motive force across the inner bacterial
membrane, the studied TrkH T350K mutation decreases
the uptake of aminoglycoside antibiotics (Lazar et al. 2013).
As a side effect, TrkH T350K diminishes the activity of protein
motive force dependent major efflux pumps, leading to hy-
persensitivity to several other antibiotics in E. coli (Lazar et al.
2013). Introduction of the TrkH T350K mutation into the S.
enterica genome leads to a significant decrease in aminoglyco-
side susceptibility in the mutant strain (table 2). However,
increased susceptibility of the mutant S. enterica strain was
observed to only four out of the nine nonaminoglycoside
antibiotics, as opposed to all nine in the case of the mutant
E. coli. In fact, under ampicillin and erythromycin stresses,
TrkH T350K induced collateral sensitivity in E. coli, but
cross-resistance in S. enterica. Other notable examples indi-
cating the limited conservation of collateral sensitivity effects
could be seen with mutants of mprA, a regulator of multidrug
resistance pumps, and phoQ, a regulatory histidine kinase
(table 2). Overall, 46% of the total mutation–antibiotic pairs
displayed a lack of conservation of collateral sensitivity or
cross-resistance between the two species.
Species-Specific Fitness Costs of Resistance Mutations
Prior studies have shown that antibiotic resistance mutations
frequently reduce fitness in antibiotic-free media (Andersson
and Hughes 2010). Indeed, growth analysis of the mutant and
wild-type strains revealed that in antibiotic-free medium, 5
and 3 out of the 10 mutants showed significantly lower fitness
than the wild-type in E. coli and S. enterica, respectively (fig. 3).
FIG. 2. Examples of dose–response curves of the generated Escherichia coli and Salmonella enterica mutants (specific mutation indicated in the
chart legends) where mutations had opposite effect compared with the wild-type ancestral strain (E. coli BW25113 and S. enterica serovar
Typhimurium LT2, respectively) on resistance against given antibiotics (indicated at the bottom of each chart). Each strain was measured in three
replicates (n¼ 3), error bars represent standard error of the mean (SEM). OD data indicated on the y axis represent optical density measurements
taken at 600 nm.
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However, only the mutation in soxR reduced fitness in both
species. In fact, a mutation in the Fis protein, a DNA-binding
protein regulating the organization of nucleoid structure
(Schneider et al. 2001) caused a significant fitness increase
in E. coli, but a significant fitness decrease in S. enterica
(fig. 3). Fis has been shown to modulate the transcription
of over 20% of all E. coli genes (Cho et al. 2008), and target
genes of global regulatory factors evolve rapidly in bacteria
(Madan Babu et al. 2006). Moreover, the amino acid sequence
similarity of Fis is 100% between E. coli and S. enterica.
Therefore, it is plausible that the difference in the fitness
effects of the Fis mutation reflect an altered set of target genes
in the two species.
Intergenic Epistasis Shapes Mutational Effects in TrkH
The above data indicate that the genetic makeup of the re-
cipient species shapes the mutational effects on antibiotic
resistance, collateral sensitivity, and fitness cost alike. The ef-
fect of the investigated mutation may be dependent on the
presence of one or more preexisting genetic changes in the
same target gene (intragenic epistasis). Alternatively, the dif-
ference in mutational effect could be due to genetic changes
elsewhere in the genome (intergenic epistasis). To tease apart
the relative contributions of intragenic and intergenic epista-
sis, we transplanted an entire resistance gene from one spe-
cies to another. We focused on the previously described trkH,
a gene with a central role in aminoglycoside resistance and
corresponding collateral sensitivity patterns to other antibi-
otics. TrkH is nonessential and shows a high level of amino
acid sequence similarity (97.5%) between S. enterica and E.
coli. As described previously, the focal TrkH T350K mutation
increases resistance to aminoglycosides, but simultaneously
yields hypersensitivity to several other antibiotics in E. coli.
Using an established recombineering method (Thomason
et al. 2014), we first replaced the entire trkH gene in the E. coli
chromosome with its S. enterica ortholog (Materials and
Methods). Importantly, both the wild-type and the TrkH
T350K mutation-carrying sequence of S. enterica trkH were
introduced into E. coli BW25113 with the exact gene bound-
aries as the original E. coli trkH gene. In sum, we generated
four strains of E. coli with isogenic genomic backgrounds, the
only difference being whether they carried S. enterica or E. coli
trkH gene with or without the TrkH T350K mutation. As the
genomic backgrounds of the four strains are identical, any
difference in mutational effect of TrkH T350K can be attrib-
uted to intragenic epistasis only (see fig. 4A for a conceptual
overview).
We measured the antibiotic resistance in all four strains
across 12 antibiotics, allowing us to compare the impact of
TrkH T350K on resistance in strains carrying the S. enterica or
the E. coli trkH gene (fig. 4B). It thereby allows for the assess-
ment of intragenic epistatic effects on antibiotic susceptibility.
As expected, TrkH T350K confers resistance to aminoglyco-
sides (kanamycin and tobramycin) and streptomycin regard-
less of the gene of origin. Moreover, it simultaneously elevated
susceptibility to a range of other antibiotics belonging to cell
wall, protein synthesis, and gyrase inhibitors. The comparison
revealed only one minor difference in mutational effects.
TrkH T350K elevated susceptibility to erythromycin only
when the strain carried the E. coli and not the Salmonella
trkH gene. We conclude that the phenotypic effects of TrkH
T350K are similar regardless of the origins of trkH itself, indi-
cating a limited impact of intragenic epistasis on resistance.
This pattern is unlikely to reflect the high sequence level of
conservation of trkH gene only, as transplantation of the S.
enterica trkH sequences into E. coli caused a significant fitness
decline (supplementary fig. 1, Supplementary Material on-
line). This indicates that despite the 97.5% amino acid se-
quence similarity, the differences in trkH sequences
between S. enterica and E. coli have functional consequences.
Future work should establish the extent to which the role of
intragenic epistasis increases with diminishing sequence iden-
tity of the genes considered.
Next, we focused on the role of intergenic epistasis by
studying the impact of the genomic background on muta-
tional effects. For this purpose, we generated E. coli and S.
enterica strains both of which carried the Salmonella trkH
gene with or without TrkH T350K. This allows comparison
of the effect of the TrkH T350K mutation in E. coli and S.
enterica. This ensured that the differences in mutational
effects were not due to species-specific differences in the
trkH gene itself (fig. 4A). This comparison revealed major
qualitative differences in the resistance and collateral sensi-
tivity profiles (supplementary table 2, Supplementary
Material online). Most significantly, TrkH T350K elevated sus-
ceptibility to ampicillin and erythromycin in E. coli BW25113
but increased resistance to the same drugs in S. enterica.More
generally, TrkH T350K elevated susceptibility to eight anti-
biotics in E. coli BW25113, but to only four in S. enterica
(fig. 4B). The relatively low evolutionary conservation of col-
lateral sensitivity patterns seen with TrkH may reflect species-
specific variation of drug uptake mechanisms (Kohanski et al.
2010).
Evolution of Multidrug Resistance on the Adaptive
Landscape
To investigate step-by-step evolution of multidrug resistance
and collateral sensitivity, we reconstructed a resistance
FIG. 3. Fitness cost of antibiotic resistance mutations in Escherichia
coli and Salmonella enterica. The figure shows the growth rates of
wild-type and individual mutant strains in E. coli (light green bars) and
S. enterica (light orange bars). Error bars represent standard deviation,
based on eight biological replicates for each strain. *Significant differ-
ence in growth rates between mutant and the corresponding wild-
type (P< 0.05, two-tailed t-tests).
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landscape across multiple antibiotics. For this purpose, we
constructed a set of E. coli strains carrying various, previously
identified antibiotic resistance mutations in all possible com-
binations (see supplementary fig. 2, Supplementary Material
online, for a conceptual overview of this experimental ap-
proach). We employed mutations previously identified in a
laboratory-evolved E. coli strain (Lazar et al. 2013). Briefly,
starting from a single clone of E. coli, ten parallel populations
were previously exposed to gradually increasing concentra-
tions of erythromycin. One isolate from each population was
subsequently subjected to detailed genomic and phenotypic
analyses (Lazar et al. 2014). Notably, each adapted strain had
distinct combinations of mutations that provided resistance
against erythromycin. Here, we focused on the ERY2 strain, as
it showed an exceptionally high frequency of resistance to
multiple drugs, while also showing hypersensitivity to others
(Lazar et al. 2014). Therefore, the mutations in ERY2 were
viable candidates to investigate how multidrug resistance
changes as adaptive evolution toward erythromycin
proceeds.
ERY2 had accumulated four point mutations during the
course of laboratory evolution. The corresponding mutated
proteins have various functions, including stress-induced reg-
ulators of multidrug transport (AcrR) and oxidative stress
(SoxR), a global modulator of nucleoid structure (Fis), and a
protein with an unknown function (YcbZ), implicated in
translational processes and ribosome biogenesis
(Gagarinova et al. 2016). As the investigated regulatory pro-
teins control the expression of multiple genes, they are
expected to have substantial pleiotropic effects when mu-
tated, making them appealing candidates for the study of
intergenic epistatic interactions. For example, nearly 900 Fis-
associated regions across the E. coli genome have been pre-
viously identified, and as noted earlier, expression of over 20%
of the genes are affected by the deletion of fis in the same
species (Cho et al. 2008). Using pORTMAGE (Nyerges et al.
2016), we constructed all possible combinations of the four
mutations, resulting in 15 total strains (supplementary table
3, Supplementary Material online). Next, the susceptibilities of
all strains were measured against the 12 antibiotics used
throughout this work (supplementary table 4,
Supplementary Material online). The susceptibility profiles
of the different combinatorial mutant strain were analyzed
to determine the extent by which cross-resistance and col-
lateral sensitivity change in response to the introduction of
new resistance mutations.
Due to the pleiotropic effect of the studied mutations, they
are expected to influence genetic susceptibility to many other
drugs as a collateral effect. This appears to be so: Single
mutants generally showed a mild, but significant increment
in resistance level to a range of other antibiotics and elevated
antibiotic susceptibility to others (supplementary table 4,
Supplementary Material online). For example, both the fis
and the soxR mutations (SoxR* and Fis*) increase erythromy-
cin resistance when introduced individually into the wild-type
genetic background (fig. 5A), but the same mutations have
opposite effects on cefoxitin resistance: SoxR* increases,
whereas Fis* decreases resistance (fig. 5A).
We first systematically studied the effects of each 32 mu-
tational step on erythromycin resistance: 31 out of the 32
steps increased resistance, and one was neutral with respect
to resistance (fig. 5A). This indicates that erythromycin resis-
tance can follow multiple mutational paths. The picture was
markedly different when we studied the impact of each 32
mutational step on cross-resistance to 11 other antibiotics
(supplementary table 4, Supplementary Material online).
Fifty-four percent of all 352 mutational step-antibiotic com-
binations increased, 32% combination decreased resistance,
while 14% led to no change. The resistance landscape under
cefoxitin acid stress highlights the general pattern. In this case,
FIG. 4. Effects of intragenic and intergenic epistasis on collateral sensitivity. (A) Strains used for analysis. Six strains were considered: (1) wild-type
Escherichia coli, (2) E. coli with trkH mutation (T350K), (3) E. coli with wild-type Salmonella trkH gene, (4) E. coli with mutant Salmonella trkH gene,
(5) wild-type a Salmonella enterica, and finally (6) trkH mutant S. enterica. Comparison of strains with E. coli genomic background reveals
intragenic epistasis, whereas comparison of strains with Salmonella trkH gene reveals intergenic epistasis. (B) Impact of TrkH T350K mutation on
resistance level in three genetic backgrounds: (i) E. coli, (ii) E. coli carrying S. enterica trkH gene, and (iii) S. enterica. Green coloring marks instances
where mutants expressed increased antibiotic resistance compared with the corresponding control, blue represents no change in antibiotic
susceptibility, whereas red boxes refer to the decreased antibiotic resistance of the given mutant, compared with the reference strain.
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(fig. 5B), 18 mutational steps were adaptive (increased resis-
tance), whereas 11 and 3 were deleterious (decreased resis-
tance) and neutral (no change in resistance), respectively.
To investigate this issue from a different angle, we an-
alyzed how individual mutations shape resistance across
different genetic backgrounds. In the case of erythromy-
cin, the pattern was very simple: Mutations increased
erythromycin resistance irrespective of the genetic back-
ground, the only exception being that the mutation in fis
was neutral in the strain that carried ycbZ and acrR mu-
tational combinations only. The picture was very different
when other antibiotics were considered. Overall, muta-
tions increased resistance level with certain combinations
of other mutations only (fig. 5B). For example, the YcbZ*,
AcrR* decreased or increased susceptibility to cefoxitin
depending on the genetic background (fig. 5A and B),
and Fis* increased cefoxitin resistance only in combina-
tion with AcrR* and SoxR* mutations.
Finally, we systematically compared the antibiotic suscep-
tibilities of the wild-type and mutant clones. For this purpose,
we estimated the corresponding changes in the sensitivities of
each mutant strain to the wild-type across all antibiotics,
ultimately leading to a map of cross-resistance and collateral
sensitivity interactions for each mutant. Comparison of the
network of these interactions across mutants revealed that
collateral sensitivity frequently changes into cross-resistance
and vice versa as evolution toward erythromycin resistance
progresses (fig. 5B and C and supplementary fig. 3,
Supplementary Material online).
These findings indicate that each adaptive mutation under
erythromycin stress has variable and largely unpredictable
effects on susceptibility to other drugs. It should be empha-
sized that other strains adapted in parallel to erythromycin
(Lazar et al. 2014) gained distinct combinations of mutations
that conferred resistance. Based on our results, it is highly
probable that these adapted lines also have unique collateral
FIG. 5. Evolution of cross-resistance collateral sensitivity on the adaptive landscape. (A) The figure shows 32 genotypes defined by all possible
combinations of four resistance mutations. The four digit codes encode a given genotype, where 0 and 1 refer to the wild-type and mutant variant
of a given gene, respectively (see also B bottom panel). Green arrows indicate adaptive mutational steps (resistance gain), red arrows indicate
maladaptive steps (resistance loss), while blue arrows are neutral steps (no change in resistance). For the raw data across all studied 12 antibiotics,
see supplementary table 4, Supplementary Material online. (B) The figure shows the impact of each mutation on resistance level in different
genotypes. Color codes are as in panel A. (For all antibiotics, see supplementary fig. 4, Supplementary Material online.) (C) Changes in cross-
resistance and collateral sensitivity interactions as genetic adaptation toward erythromycin progresses. The neighboring genotypes are one
mutational step away from each other, and hence they form an adaptive route from wild-type (0000) toward a genotype with high erythromicin
resistance level (1111). We compared the resistance level of the mutant genotypes (0010, 0110, 0111, 1111) to the wild-type (0000) across 11
antibiotics. Erythtromycin was excluded from the analysis, as all genotypes show reduced susceptibilities to this drug (A). Green and red lines
indicate cross-resistance and collateral sensitivity, respectively. For more details and examples, see supplementary figure 3, Supplementary
Material online.
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sensitivity networks. This underscores the notion that cross-
resistance and collateral sensitivity interactions are highly var-
iable and dependent on the genetic background.
Discussion
In this work, through the combination of complementary
experimental approaches, we studied the evolutionary con-
servation of mutational effects on bacterial resistance against
a wide range of antibiotics. First, we directly compared the
phenotypic effects of specific antibiotic resistance mutations
in two related species, E. coli and S. enterica, and found sig-
nificant differences (fig. 2). We found that certain mutations
increased resistance against an antibiotic in one species,
whereas introduction of the same mutation into the other
species increased sensitivity to the same antibiotic. Second,
we investigated a mutation (TrkH T350K) that causes resis-
tance to aminoglycosides, but collateral sensitivity to a range
of other antibiotics in E. coli. By introducing the same muta-
tion into S. enterica, we found that only a fraction of these
collateral effects remained conserved, mainly due to inter-
genic epistatic effects. Finally, by reconstructing a mutational
landscape, we studied how individual mutational steps
change resistance to multiple antibiotics. We found that col-
lateral sensitivity and cross-resistance effects strongly depend
on the genetic background. Even a single resistance mutation
can alter collateral responses to other antibiotics.
Taken together, our results point to the limited conserva-
tion of mutational effects driving collateral sensitivity and
cross-resistance phenotypes of antibiotic-resistant bacteria.
Several lines of evidence point to the same direction. First,
evolution of resistance is frequently achieved through diver-
gent molecular mechanisms leading to substantial differences
in the collateral sensitivity patterns (Nichol et al. 2019).
Second, a previous study showed that one third of the 60
studied collateral responses could be considered conserved
(i.e., observed in at least 5 out of 10 different clinical isolates of
E. coli adapted to the same antibiotic [Podnecky et al. 2018]).
Our own results indicate a lower level of conservation, which
is likely due to major differences in the extent of genetic
distance spanned in the two studies. In particular, we com-
pared the conservation of susceptibility phenotypes between
E. coli and S. enterica, two species that differ by 16% at the
nucleotide level (McClelland et al. 2000), whereas even the
most diverged E. coli strains from Podnecky et al. (2018) ac-
cumulated<0.04 substitutions per site. Third, by studying the
antibiotic resistance profiles of clinical P. aeruginosa isolates,
Imamovic and colleagues found that susceptibilities of indi-
vidual strains isolated from the same patient in a longitudinal
study varied greatly over time (Imamovic et al. 2018). These
changes in resistance levels point to the dynamic nature of
collateral sensitivity, most likely owing to various genomic
mutations occurring over time. Fourth, there are substantial
differences in the efficacy of collateral sensitivity treatment
across species. For example, evolution of resistance to cipro-
floxacin induces collateral sensitivity against doxycycline in E.
coli, but cross-resistance in Staphylococcus aureus (Rodriguez
de Evgrafov et al. 2015). Similarly, aminoglycosides and
piperacillin display cross-resistance in a P. aeruginosa strain,
but collateral sensitivity in E. coli (Barbosa et al. 2017).
Additionally, in the same study, the authors observed instan-
ces where parallel samples of P. aeruginosa PA14 adapted to
the same antibiotic (e.g., cefsulodin) showed opposite
changes in susceptibility against other antibiotics (including
gentamicin and streptomycin). This shows that various
modes of adaptation to the same antibiotic entail differ-
ences in the corresponding collateral sensitivity profiles.
Finally, a recent study by Knopp and Andersson examined
the effects of antibiotic resistance mutations when intro-
duced into a range of related bacterial species and strains
(Knopp and Andersson 2018). Mutational effects of resis-
tance mutations in regulatory proteins were relatively
variable, whereas target mutations had relatively con-
served effects across species.
Taken together, these findings support the dynamic nature
of collateral response in antibiotic-resistant bacteria. This phe-
nomenon may not be limited to prokaryotes. A recent study
showed that during different intermediate stages of clonal
evolution, a subpopulation of cancer cells resistant to BCR-
ABL1-targeted inhibitors developed collateral sensitivity
against other anticancer agents. However, the extent of col-
lateral sensitivity was dependent on the specific genotype of
the evolved clones (Zhao et al. 2016).
It is important to emphasize that there are instances where
the underlying molecular mechanisms of collateral sensitivity
are conserved across strains and therefore such cases may be
promising starting points for clinical treatments. For example,
clinical samples of P. aeruginosa resistant to ciprofloxacin iso-
lated from cystic fibrosis patients were shown to have con-
served collateral sensitivity against aminoglycosides, allowing
this approach to be utilized for effective in vivo treatment of a
chronic cystic fibrosis patient (Imamovic et al. 2018). Indeed,
our own data lend further support to these examples, as
antibiotic resistance mutations in fis and acrR displayed highly
conserved collateral responses against ciprofloxacin, irre-
spective of the genetic background (supplementary table
4, Supplementary Material online). Narrowing down col-
lateral responses to the most robust and conserved such
as this example is imperative for successful clinical out-
comes if bacterial collateral sensitivity responses are to be
used as treatment strategies. This is all the more relevant
in clinical settings where infections are frequently poly-
microbial in nature (Rogers et al. 2010), further increasing
the need for the identification of highly conserved collat-
eral interactions. Finally, it should be noted that conclu-
sions based on our findings have limitations. For example,
for strains exhibiting significantly higher resistance, the
possibility that collateral sensitivity interactions would
be less dependent on the genetic makeup of strains can-
not be ruled out. Nonetheless, we show that such factors
must be taken into account, as they have the potential to
greatly influence the outcome of therapies that apply
combinations of antibiotics. Overall, the dynamic nature
of the majority of collateral sensitivity interactions will be
an important aspect to consider when designing multi-
drug treatments against bacterial pathogens.













Unless otherwise noted, bacterial cell cultures were grown in
Lysogeny-Broth-Lennox (LBL) media (10 g tryptone, 5 g yeast
extract, and 5 g sodium chloride per 1 l water) for cell manip-
ulations and growth measurements. Terrific-broth media
(24 g yeast extract, 12 g tryptone, 9.4 g K2HPO4, and 2 g
KH2PO4 per 1 l of water) was used for cell recovery following
electroporation.
Strain Construction, Oligonucleotides
For a full list of oligonucleotides used in the study (with brief
descriptions), see supplementary File 2, Supplementary
Material online. Bacterial strains used in the study were con-
structed on background strains E. coli K-12 BW25113 or S.
enterica serovar Typhimurium LT2 using the pORTMAGE
recombineering method described previously (Nyerges et al.
2016). Briefly, individual antibiotic resistance mutations were
introduced via synthetic ssDNA oligonucleotides (oligos), or-
dered with standard purification and desalting from
Integrated DNA Technologies. These oligos were designed
using the MODEST online tool (Bonde et al. 2014) and
were 90 nucleotides long and had complementary sequences
(save for the mutations of interest) to the replicating lagging
strand with a minimized secondary structure (>8 kcal/
mol). Each oligo also contained two subsequent phosphoro-
thioate bonds at both 50 and 30 termini for the evasion of
endogenous nuclease-mediated oligo processing.
Recombineering was performed in electrocompetent cells
carrying the pORTMAGE-2 plasmid (Addgene ID #72677),
incubated at 42 C for 15 min to induce expression of the k
Red recombinase enzymes, as well as a dominant negative
allele of the MutL mismatch-repair enzyme for the negation
of off-target mutations (Nyerges et al. 2016). The induced
electrocompetent cells were then transformed with 1ll of
the 100-lM mutation-carrying oligo. Cells were recovered in
5-ml terrific-broth media after electroporation and incubated
at 30 C for 60 min, after which 5-ml LBL media was added
and incubation at 30 C continued overnight. Cultures were
then plated onto solid LBL agar media plates from which
individual colonies could be genotypically analyzed.
Colonies carrying the desired mutations were screened
using either allele-specific polymerase chain reaction (PCR)
or high resolution melting (HRM) analysis. Briefly, allele-
specific primers were designed and tested using wild-type
colonies using a gradient PCR protocol using a Bio-Rad
CFX96 Touch thermocycler. PCR annealing temperatures
for colony screening were set at a temperature 1 C higher
than the temperature where the last visible fragment could
be detected using the wild-type colony after gradient PCR.
Alternatively, HRM colony-PCR was used to screen colonies
with the Luminaris HRM Master Mix (Thermo Fisher
Scientific) using a Bio-Rad CFX Touch thermocycler according
to the manufacturer’s instructions. Candidate colonies were
subsequently verified using capillary-sequencing.
Strains with genotypes carrying multiple mutations were
constructed sequentially, that is each mutation-carrying oligo
was transformed separately, the mutations were screened
and verified and the following oligo was then transformed,
etc. The pORTMAGE-2 plasmid was cured from sequence-
verified colonies by growing the cells once overnight at 42 C.
Gene Replacement
Gene replacement of the entire trkH sequence (along with
the corresponding upstream regulatory sequence) was car-
ried out using both the wild-type and resistance point
mutation-carrying S. enterica sequence, into a wild-type E.
coli background. Gene replacement was achieved using a
two-step selection/counter-selection recombineering
method (Thomason et al. 2014) involving a tetA-sacB cassette
(Li et al. 2013).The tetA-sacB cassette was PCR amplified using
Phusion High-Fidleity DNA polymerase (Thermo Scientific)
using the E. coli T-SACK strain (Li et al. 2013) as a template (a
kind gift from Donald L. Court, National Cancer Institute,
Frederick, MD). The cassette was amplified using primers
with 60-bp 50 overhangs carrying homologies to the E. coli
trkH sequence. k-Red-mediated recombineering of the puri-
fied fragment was achieved using the pSIM-5 plasmid (Datta
et al. 2006) using a well-established protocol (Thomason et al.
2014). Tetracyclin-resistant trkH insertants were verified by
testing for sucrose sensitivity as well as trkH and cassette-
specific PCR. Recombineering was then repeated on verified
strains carrying the tetA-sacB cassette, transforming PCR-
amplified S. enterica wild-type and mutant trkH cassettes.
These cassettes were previously amplified using primers
with 50-bp 50 overhangs carrying homologies to the sequen-
ces directly flanking E. coli trkH. Cells were plated onto a
special Tet/SacB counter-selection medium (Li et al. 2013)
and incubated at 42 C for 48 h. Colony-PCR was then per-
formed on individual colonies using a forward primer specific
to S. enterica trkH and a reverse primer specific to the E. coli
trkH flanking region. Colonies that produced an amplified
fragment (around 10% of tested colonies) were then verified
for the desired outcome using Sanger sequencing.
MIC Measurement
Measurement of MIC values was performed using a standard
linear broth dilution method (Wiegand et al. 2008). Twelve
linear dilution steps, with a dilution rate of 1.2, were prepared
in 96-well microtiter plates. Approximately 3 103 cells were
inoculated into volumes of 1 ml using a 96-pin replicator tool.
Cultures were grown in a shaking incubator at 30 C shaken
at 300 rpm, with three replicates per strain for all antibiotic
concentrations. Following 24 h of incubation, raw OD600 val-
ues were measured using a Biotek Synergy 2 microplate
reader. The MIC value was determined using a cutoff OD600
value, defined as the mean þ 2 standard deviations of OD600
values of bacteria-free wells containing only growth medium.
In order to measure the effect of each individual mutation,
the MIC value of each mutant was determined compared
with the wild-type strain (referred to as relative MIC value).
The sensitivity of each mutant was measured against a set of
12 antibiotics representing a wide variety of mode of actions
(see table 1). See supplementary File 1, Supplementary
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Material online, for raw data of all MIC measurements con-
ducted in this study.
Growth Rate Measurement
Growth rate measurements of selected strains were per-
formed by growing replicates (n¼ 24) of randomly chosen
individual colonies in LBL media. Cultures of the studied
mutants were incubated at 30 C until early stationary phase,
followed by the transfer of 103 cells from each into 96-well
shallow plates containing 100-ll LBL media. Growth curves
were recorded by measuring OD600 every 7 min for 24 h at
30 C using a Biotek Powerwave XS2 automated plate reader.
Growth rate was calculated from the obtained growth curves
following a previously reported procedure (Warringer and
Blomberg 2003; Karcagi et al. 2016).
Supplementary Material
Supplementary data are available at Molecular Biology and
Evolution online.
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